Taken together, IMP3 was validated to be an independent prognostic factor for localized CCRCC patients, and patients with IMP3 positive tumors have a shorter survival than those with IMP3 negative tumors. The gene discussed is IMP3; the disease is nonpapillary renal cell carcinoma.